

(43) International Publication Date
29 December 2011 (29.12.2011)(10) International Publication Number
WO 2011/161537 A2

(51) International Patent Classification:

C07D 487/04 (2006.01) **A61P 29/00** (2006.01)
A61K 31/4985 (2006.01) **C07D 241/06** (2006.01)
A61P 9/00 (2006.01) **C07D 207/337** (2006.01)
A61P 25/00 (2006.01) **A61P 25/28** (2006.01)

(21) International Application Number:

PCT/IB2011/001594

(22) International Filing Date:

1 June 2011 (01.06.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1054372 3 June 2010 (03.06.2010) FR

(71) Applicant (for all designated States except US):
SANOFI [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COTE-DES-COMBES, Sylvain** [FR/FR]; c/o Sanofi, Patent Department, 174 avenue de France, F-75013 Paris (FR).
FROISSANT, Jacques [FR/FR]; c/o Sanofi, Patent Department, 174 avenue de France, F-75013 Paris (FR).
GIBERT, Jean-François [FR/FR]; c/o Sanofi, Patent Department, 174 avenue de France, F-75013 Paris (FR).
MARGUET, Frank [FR/FR]; c/o Sanofi, Patent Department, 174 avenue de France, F-75013 Paris (FR).
PACAUD, Christophe [FR/FR]; c/o Sanofi, Patent De-

partment, 174 avenue de France, F-75013 Paris (FR).
PUECH, Frédéric [FR/FR]; c/o Sanofi, Patent Department, 174 avenue de France, F-75013 Paris (FR).
RAVET, Antoine [FR/FR]; c/o Sanofi, Patent Department, 174 avenue de France, F-75013 Paris (FR).

(74) Agent: **TINEL, Marie Line**; c/o Sanofi, Patent Department, 174 avenue de France, F-75013 Paris (FR).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF



(57) Abstract: Compounds corresponding to the general formula (I) in which R₂ represents a group C₁₋₁₀-alkyl, C₃₋₁₀-cycloalkyl, C₃₋₇-cycloalkyl-C₁₋₆-alkyl, C₁₋₆-alkyl-C₃₋₇-cycloalkyl, C₃₋₇-cycloalkyl-C₃₋₇-cycloalkyl, C₁₋₆-alkylthio-C₁₋₁₀-alkyl, C₁₋₆-alkoxy-C₁₋₁₀-alkyl, hydroxy-C₁₋₁₀-alkyl, hydroxy-C₁₋₆-alkyl-C₃₋₇-cycloalkyl-C₁₋₆-alkyl, hydroxy-C₃₋₁₀-cycloalkyl, C₁₋₁₀-fluoroalkyl or C₃₋₁₀-fluorocycloalkyl; an optionally substituted heterocyclic group; a group C₁₋₁₀-alkyl substituted with an optionally substituted heterocyclic group; Xe represents a group chosen from hydrogen, fluorine, chlorine and bromine atoms or a group C₁₋₆-alkyl, C₃₋₇-cycloalkyl, C₃₋₇-cycloalkyl-C₁₋₆-alkyl, C₁₋₆-fluoroalkyl or cyano; and R₇ represents an aryl group such as phenyl or naphthyl, optionally substituted with one or more substituents, in the form of the base or of an acid-addition salt. Therapeutic use.



— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*